Xoanacyl (ferric citrate coordination complex)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- ferric citrate coordination complex
- Company
- Averoa
- Status
- Authorised
- Therapeutic area
- Iron Deficiencies; Renal Insufficiency, Chronic; Hyperphosphatemia
- CHMP opinion
- Thu 27 Mar 2025
- EU approval
- Wed 11 Jun 2025
- Designations
- Additional monitoring
- Application
- EMEA/H/C/006402
- ATC
- V03AE08
- Official record
- www.ema.europa.eu
Indication
Xoanacyl is indicated for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Fexeric Lapsed · Akebia Europe Limited
Follow Xoanacyl
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.